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Abstract
Objective—Therapeutic arteriogenesis, i.e., expansive remodeling of pre-existing collaterals,
using single-action factor therapies has not been as successful as anticipated. Modulation of
factors that act as a master switch for relevant gene programs may prove more effective.
Transcriptional co-activator P300/CBP-associated factor (PCAF) has histone acetylating activity
and promotes transcription of multiple inflammatory genes. Because arteriogenesis is an
inflammation-driven process, we hypothesized that PCAF acts as multifactorial regulator of
arteriogenesis.
Approach and Results—After induction of hind limb ischemia, blood flow recovery was
impaired in both PCAF−/− mice and healthy wild type mice treated with the pharmacological
PCAF inhibitor Garcinol, demonstrating an important role for PCAF in arteriogenesis. PCAF
deficiency reduced the in vitro inflammatory response in leukocytes and vascular cells involved in
arteriogenesis. In vivo gene expression profiling revealed that PCAF deficiency results in
differential expression of 3505 genes during arteriogenesis and, more specifically, in impaired
induction of multiple pro-inflammatory genes. Additionally, recruitment from the bone marrow of
inflammatory cells, in particular “pro-inflammatory” Ly6Chi monocytes, was severely impaired in
PCAF−/− mice.
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Conclusions—These findings indicate that PCAF acts as master switch in the inflammatory
processes required for effective arteriogenesis.
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Introduction
Peripheral arterial occlusive disease is a leading cause of morbidity and mortality. Blood
flow to ischemic tissues in the affected limb can be restored by distinct processes1, namely
vasculogenesis, angiogenesis and arteriogenesis, of which arteriogenesis, the remodeling of
pre-existing collateral arterioles into larger arteries, has the greatest impact2.
Effective arteriogenesis requires coordination of multiple events. Arteriogenesis is triggered
by an increase in fluid shear stress across pre-existing collaterals cross-connecting adjacent
arterial trees, which is caused by a pressure gradient created by occlusion or atherosclerotic
stenosis of one of the trees. This leads to activation of the endothelial cells and adjacent
vascular smooth muscle cells (VSMCs) of the collateral wall. Induction of adhesion
molecules, cytokines and chemokines then follows as the first step of an inflammatory
cascade essential for arteriogenesis. Recruitment of leukocytes from blood and bone marrow
follows, in particular monocytes3-6 but also CD4+, CD8+ and regulatory T cells and natural
killer cells7-11. These cells infiltrate into the perivascular space around collaterals and
release additional paracrine signaling molecules and growth factors. Subsequent degradation
and reorganization of the extracellular matrix by released matrix metalloproteases (MMPs),
including MMP2 and MMP9, creates space required for expansive remodeling of the pre-
existing collaterals. Proliferation of collateral endothelial cells, VSMCs and fibroblasts is
stimulated, resulting in an increased anatomic lumen diameter. All of the steps described
above underline the crucial role of inflammation in effective arteriogenesis.
Although stimulation of collateral remodeling is regarded as a promising therapeutic
alternative to surgical interventions, clinical trials aimed at modulating individual growth
factors or cytokines have thus far not been as successful as anticipated12. We now know that
the coordinated inflammatory and immune modulatory processes driving collateral growth
are multifactorial and too complex to be modulated by therapeutics that target a single gene
or pathway. In contrast, modulation of a factor that acts as a master switch for multiple
relevant gene programs may be a more effective strategy to augment arteriogenesis.
A protein with such master switch potential is P300/CBP-Associated Factor (PCAF), a
transcriptional co-activator with intrinsic histone acetyltransferase activity. PCAF acetylates
histones H3 and H4, but there is also increasing evidence that PCAF modulates non-histone
proteins13-16, including hypoxia-inducible factor 1α (Hif-1α)17 and Notch18. Furthermore,
the histone acetylating activity of PCAF is essential for NF-κB-mediated gene
transcription19 and facilitates inflammatory gene regulation20. Since arteriogenesis is an
inflammatory-like process, we hypothesized that PCAF acts as master switch that stimulates
multiple inflammatory processes important for collateral remodeling.
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Recently, it was shown in a large patient population study (>3000 individuals)21 that a
variation in the promoter region of PCAF is associated with coronary heart disease-related
mortality22. In support of this observation, we recently demonstrated a role for PCAF in
vascular remodeling in a mouse model for reactive stenosis. However, whether PCAF
participates in arteriogenesis has not yet been investigated.
In the present study, we investigated the contribution of PCAF to post-ischemic
neovascularization in a hind limb ischemia (HLI) model23, using PCAF deficient (PCAF−/−)
mice. When studying arteriogenesis in a knockout model, it is possible that the gene deletion
may affect vascular development in the embryo, including collaterogenesis, thus affecting
the number of collaterals available for remodeling after an occlusive event in the adult. To
investigate whether observed effects were caused by differences in arteriogenesis, in the
native collateral circulation or a combination of both, we examined the pre-existing
collateral density as well as the effect of administration of the PCAF inhibitor Garcinol to
wild type (WT) mice after induction of HLI. We also studied gene expression and leukocyte
recruitment in PCAF−/− and WT mice after induction of HLI to examine potential
mechanisms by which PCAF regulates arteriogenesis.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results
PCAF contributes to collateral remodeling
PCAF−/− mice showed impaired blood flow recovery after HLI (Figure 1A-B).
Postoperative blood flow was decreased to approximately 6% of blood flow in the
contralateral limb in both groups, with a trend towards reduced blood flow in PCAF−/−mice
compared to WT mice (Figure 1C, p=0.07). Thereafter, blood flow recovery in PCAF−/−
mice was reduced and did not recover completely before termination at 28 days. Moreover,
PCAF−/− mice showed significantly more necrotic toe nails than WT mice (PCAF−/− 2.9
±0.6 vs WT 0.45±0.2, p<0.001) (Figure 1D). No auto-amputation of hind limb digits was
observed in either group. The reduced blood flow recovery in PCAF−/−mice was confirmed
by quantification of smooth muscle α-actin positive (αSMA+) vessels in the adductor
muscle group, 28 days after HLI (Figure 1E). Both the number of αSMA+ vessels (Figure
1F) and the diameter of αSMA+ vessels (Figure 1G-H) in PCAF−/− mice were significantly
reduced, resulting in a reduced blood flow. The mean lumen area per αSMA+ vessel
(PCAF−/− 139±15μm2 vs WT 297±26μm2, p<0.001) and total lumen area per section
(PCAF−/− 447±46μm2 vs WT 1253±117μm2, p<0.001) were severely reduced in PCAF−/−
mice (Figure 1G-H). Thus, PCAF deficiency leads to reduced arteriogenesis after induction
of HLI.
To assess whether the reduction in blood flow recovery in PCAF−/− mice was caused by
reduced collateral remodeling or by fewer pre-existing collaterals, we performed two
additional experiments. First, we inhibited PCAF by pharmacological intervention with
Garcinol to rule out any effects on number of pre-existing collaterals in the PCAF−/− mice.
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In WT mice, local PCAF inhibition by Garcinol resulted in reduced blood flow restoration
compared to the empty pluronic gel control group (Figure 2A-B). Second, the preexisting
vascular bed of PCAF−/− and WT mice was assessed in the pial circulation using an arterial
vascular casting (Figure 2C). Pial collateral density in PCAF−/− mice was reduced by 11%
compared to WT mice, reflecting a moderate but significant contribution of PCAF in
determining the abundance of the native collateral circulation (Figure 2D-E, p=0.02). This
was in agreement with the trend towards decreased blood flow perfusion in PCAF−/− mice
directly after HLI.
PCAF is required for in vitro inflammatory response
We investigated the role of PCAF in the inflammatory response of multiple cell types, given
the above evidence for decreased collateral remodeling and the known involvement of these
cells in arteriogenesis. Analysis of circulating cells in a whole blood LPS stimulation assay
showed dose-dependent increase of TNFα in blood from WT mice, which was significantly
reduced in blood from PCAF−/− mice (Figure 3A). Next, the splenic cell reservoir was
subjected to LPS stimulation and pharmacological PCAF inhibition with Garcinol. LPS (300
ng/ml)-stimulated MCP-1 levels of splenocytes from both PCAF−/− mice (63±32pg/ml) and
WT splenocytes treated with 20 μM Garcinol (195±35 pg/ml) were both significantly
reduced in comparison to WT splenocytes (372±13 pg/ml, p=0.005 and p=0.04 respectively)
(Figure 3B). Also the inflammatory phenotype of PCAF−/− VSMCs was assessed. Similar to
the splenocyte stimulation, MCP-1 levels were markedly reduced after LPS (0.1 ng/ml)
stimulation of PCAF−/− VSMCs (689±49 pg/ml) and WT VSMCs when exposed to 15μM
Garcinol (3087±284 pg/ml) compared with untreated WT VSMCs (4175±264 pg/ml,
p<0.001 and p=0.049 respectively) (Figure 3C). In addition, upregulation of MCP-1 mRNA
was significantly reduced by 53% in PCAF−/− VSMCs (Figure 3D, p=0.01). To exclude
non-specific effects of Garcinol, these experiments were repeated in WT VSMCs treated
with siRNAs against PCAF mRNA instead of Garcinol. Transfection with siRNAs targeting
PCAF mRNA efficiently decreased PCAF mRNA expression by 61% and, like Garcinol,
inhibited MCP-1 production (Supplemental Figure IA-C).
PCAF modulates post-ischemic gene regulation
PCAF staining showed enhanced expression in cells of large developing collaterals in the
adductor muscle group compared to surrounding skeletal muscle (Figure 4A). To study
differential gene expression after HLI between PCAF−/− and WT mice, total RNA isolated
from the adductor muscle group was used in a whole-genome expression analysis using
Illumina Beadchips. Statistical analysis by SAM on t1/t0avg ratios identified 1963 genes
with a significant lower ratio and 1542 genes with a higher ratio in PCAF−/−relative to WT
mice (q<5%), indicating that PCAF exhibits a large effect on gene transcription after HLI
(Figure 4B).
Supplemental Table I shows the top 50 genes with impaired upregulation in PCAF−/− mice
compared to WT mice, including MMP9, critical in matrix degradation required for
collateral artery expansion. Since PCAF has been shown to regulate inflammatory gene
transcription, we selected inflammatory genes that were significantly regulated
(Supplemental Table II and Supplemental Figure II). Among the inflammatory genes
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showing a more pronounced induction in WT mice compared to PCAF−/− mice were genes
encoding cytokines CXCL12, CCL9 and TNFα, chemokine receptor CXCR1, transcription
factor IRF7, TNF receptor associated factors TRAF2 and TRAF3, TNF receptor associated
protein TRAP1 and members of the TNF receptor superfamily TNFRSF19 and TNFRSF11a
(also known as RANK). The total of inflammatory genes with greater induction in PCAF−/−
mice was much smaller than the number of genes more strongly induced in WT, and
included inhibitors of the NF-κB pathway like NFKBIA and NKIRAS1. Aberrant regulation
of several relevant regulated factors (MMP9, TNFα, CCL9, CXCL12, IRF7) were
confirmed using real-time quantitative PCR (Figure 4C-G).
PCAF deficiency alters leukocyte recruitment
We quantified leukocyte subtypes that are involved in arteriogenesis, including T cells
(helper CD4+, cytotoxic CD8+ and regulatory T cells) and natural killer cells, and subtypes
which have not been previously implicated in arteriogenesis, including B cells and dendritic
cells. Blood samples from before (t0) and 1 day after (t1) HLI, were analyzed by FACS.
PCAF deficiency had effects on most of the leukocyte subtypes examined. Following HLI,
circulatory T cells were significantly decreased in PCAF−/− mice compared to WT mice.
This difference was caused mainly by a reduction in CD4+ T cells, especially by the fraction
of activated CD4+ T cells, defined by the loss of CD62L (L-selectin), and regulatory T cells
(CD4+CD25+FoxP3+ T cells). The number of circulatory CD8+ T cells did not differ
between WT and PCAF−/− mice. Also counts of other leukocyte subtypes, including B cells
and natural killer cells were decreased by PCAF deficiency.
To investigate the migratory behavior of the leukocyte subtypes, the spleen, bone marrow
and lymph nodes were harvested from both mouse strains before (t0) and 1 day after (t1)
HLI. Compared to WT mice, we observed reduced numbers of dendritic cells in the draining
inguinal lymph nodes of PCAF−/− mice after HLI. Accordingly, the fraction of dendritic
cells expressing the co-stimulatory molecule CD86+ was smaller in the draining lymph
nodes of PCAF−/− mice. Furthermore, nearly all tested leukocytes subtypes were increased
in the bone marrow of PCAF−/− mice compared to WT mice, including CD4+ and CD8+ T
cells, natural killer cells and dendritic cells, suggesting that these subpopulations are
retained in the bone marrow of PCAF−/− mice during recovery after HLI (Supplemental
Figure IIIA-I).
Because monocytes play a key role in arteriogenesis and are among the first leukocytes
recruited to remodeling collaterals, we evaluated different monocyte populations in blood,
spleen and bone marrow. After HLI, the absolute number of circulating monocytes in WT
mice was equal to baseline numbers, but monocytes in PCAF−/− mice significantly
decreased compared to baseline (PCAF−/− 0.13±0.05 vs WT 0.37±0.02×106/mL, p=0.002)
(Figure 5A). In WT mice, the monocyte population increased in the spleen and decreased in
the bone marrow after HLI. In contrast, bone marrow monocytes in PCAF−/−mice increased
compared to baseline and were significantly higher after HLI compared to WT mice (Figure
5B-C). The differences in monocyte numbers were caused mainly by the specific subtype of
“pro-inflammatory” Ly6Chi monocytes (Figure 5D-F). The activation state of total and
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Ly6Chi monocytes did not differ between the two strains, measured by mean fluorescent
intensity of the adhesion molecule CD11b (Figure 5G-H).
Finally, we assessed the number of monocytes/macrophages in the adductor muscle group
by fluorescent staining with antibodies against MOMA-2 and smooth muscle α-actin (Figure
6A). Although PCAF−/− mice showed a significant increase in MOMA-2-positive cells 24
hours after HLI, the increase in WT mice was significantly higher (PCAF−/− 3.2±0.35 vs
WT 6.0±0.43 / section, p=0.001) (Figure 6B). Differences were most evident in the
perivascular space of remodeling collaterals (PCAF−/− 1.4±0.16 vs WT 3.5±0.76 / section,
p=0.01) (Figure 6C).
Discussion
We demonstrate that blood flow recovery after induction of HLI is strongly impaired in
PCAF−/− mice, in association with reduced expansive remodeling of collaterals.
Furthermore, local PCAF inhibition by Garcinol in WT mice also reduces recovery,
indicating that PCAF is directly required for normal arteriogenesis. PCAF gene deficiency
results in a repressed in vitro inflammatory response in many cell types known to be
involved in arteriogenesis. One day after induction of HLI, 3505 genes are differentially
regulated in the adductor muscle group of PCAF−/− mice compared to WT mice.
Additionally, recruitment of different pro-arteriogenic leukocyte subtypes in PCAF−/−mice,
in particular “inflammatory” monocytes, is significantly impaired at this time. Our data
therefore demonstrate that PCAF plays a key role in post-ischemic arteriogenesis.
Compared to WT mice, PCAF−/− mice showed an impaired blood flow recovery after HLI.
Our findings suggest that two deficiencies caused by a lack of PCAF are involved. First, the
expansive remodeling of αSMA+ arterioles at the center of the adductor muscle group, of
which most are collaterals, was reduced by 53% in PCAF−/− mice compared to WT mice.
Correspondingly, local application of PCAF inhibitor Garcinol in healthy WT mice also
resulted in impaired blood flow recovery compared to control animals. Hence, PCAF has a
major impact on arteriogenesis. Second, we observed that the density of native pre-existing
collaterals in the pial circulation of PCAF−/− mice was reduced by 11%. Even changes of
this magnitude have significant effects on collateral-dependent perfusion of tissue
downstream from an arterial obstruction24-26. Previous studies have shown that genetic-
dependent variation in collateral number in the cerebral pial circulation is shared, at least
qualitatively, by similar differences in collateral density in other tissues24-26. Accordingly,
we also observed a trend towards a decrease in blood flow directly after induction of HLI in
PCAF−/− mice. In mice, the density of the native collaterals in tissues varies widely among
strains from differences in genetic background24-26. Hence, besides collateral remodeling,
genetic PCAF deficiency also contributes to reduced formation of the collateral circulation
which occurs during embryonic development.
In a clinical setting, the outcome after an ischemic event varies among individuals, and
differences in abundance of the native collateral circulation have also been reported in
patients27, 28. Moreover, a previous study found that the −2481G allele in the promoter
region of the PCAF gene associates with an increased risk of mortality in patients with
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coronary heart disease22, which further supports our findings that PCAF deficiency impairs
collateral function.
In order for PCAF to serve as a master switch in collateral remodeling, it needs to impact
multiple critical phases in the process, namely activation of the endothelium and vessel wall,
leukocyte recruitment, matrix degradation and arteriolar expansion. We examined gene
expression in the adductor muscle group containing remodeling collaterals in the initial
phase after HLI. Over 3500 genes were differentially regulated between PCAF−/−and WT
mice. This suggests that PCAF impacts expression of a large number of genes activated in
this setting. More specifically, PCAF−/− mice showed impaired induction of multiple pro-
arteriogenic and pro-inflammatory genes, including matrix metalloproteinase 9 (MMP9) and
chemokines CXCL12 (SDF1) and CCL9.
MMP9 is critical in degradation and remodeling of the extracellular matrix allowing cell
migration and outward expansion of the collaterals and thus effective arteriogenesis29.
CXCL12 is elevated in ischemic skeletal muscle of patients with critical limb ischemia30
and acts as chemoattractant for CXCR4+ cells, including leukocytes and progenitor cells.
CXCL12-mediated recruitment of bone marrow-derived cells to ischemic tissues results in
enhanced neovascularization31, 32. Also CCL9, which is a strong chemoattractant for bone
marrow derived cells33, is upregulated after muscle injury34.
In addition, PCAF−/− mice showed impaired induction of multiple factors related to the pro-
inflammatory TNFα pathway35. TNFα−/− mice have reduced collateral artery perfusion36
and anti-TNFα therapy attenuates arteriogenesis37. Thus, reduced TNFα expression in
PCAF−/− mice likely contributes to the impaired arteriogenesis in these mice. Our data
suggest that PCAF regulates many factors that have previously been described to play an
important role in both inflammation and arteriogenesis38.
It should be noted that RNA was isolated from the adductor muscle group as a whole38 and
not from the embedded collateral arteries alone, as was described previously39. In that
report, a whole-genome microarray analysis was performed on collaterals microdissected
from the gracilis muscle 24 hours after HLI. Here we found exceedingly more differentially
expressed genes, then the 404 genes that were found upregulated in gracilis collaterals of
WT mice39. Using the entire adductor muscle group for microarray analysis, not only the
collaterals but also infiltrating leukocytes and surrounding nonvascular tissues were
included in these analyses.
As discussed in the introduction, an inflammatory-like process plays a role in all stages of
arteriogenesis. To investigate the impact of PCAF on the inflammatory response of the
different cell types involved in arteriogenesis, we studied circulating cells in whole blood,
splenic leukocytes and VSMCs in vitro. PCAF is critical for the regulation of transcription
factor NF-κB, that consists of a p65 and p50 subunit bound to inhibitory proteins in the
cytoplasm. Upon stimulation NF-κB is translocated to the nucleus and regulates the
expression of multiple genes, including TNFα and MCP-120, 40. PCAF binds to the NF-κB
p65 subunit and activates NF-κB-related inflammatory gene expression19,20. We clearly
demonstrate that PCAF deficiency results in decreased production of pro-inflammatory
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cytokines by multiple cell types after stimulation with LPS. LPS stimulated whole blood
from PCAF−/− mice produced less TNFα than blood from WT mice, indicating a reduced
inflammatory phenotype of circulating cells. Also PCAF−/− cells isolated from the spleen,
one of the major leukocyte reservoirs, showed a reduced inflammatory response compared
to splenocytes from WT mice. PCAF−/− VSMCs produced less MCP-1 than WT VSMCs in
response to LPS, which would favor reduced monocyte recruitment and therefore reduced
VSMC proliferation, which is essential for collateral remodeling. We obtained similar
results using either Garcinol or PCAF-specific siRNA knockdown in WT VSMCs, thus
excluding effects of any pre-existing differences in PCAF deficient cells. Our data
correspond with a report that TNFα-induced NF-κB activity increases in human airway
smooth muscle cells overexpressing PCAF41 and provide strong evidence for a wide effect
of PCAF on inflammatory gene transcription.
The p65 subunit of NF-κB recruits co-activator PCAF and activates NF-κB-mediated gene
transcription. In contrast, the NF-κB p50 subunit lacks the transcriptional activation domain
and inhibits gene transcription42. Mice deficient of the NF-κB p50 subunit showed enhanced
blood flow recovery after HLI as the result of increased monocyte recruitment to the
perivascular space of collaterals43. Whereas arteriogenesis and monocyte recruitment is
enhanced by NF-κB activation in NF-κB p50−/− mice, reduced regulation of the NF-κB p65
subunit in PCAF−/− mice could likely explain the impaired arteriogenesis by inhibition of
monocyte recruitment. In WT mice, the monocyte population increased in the spleen and
decreased in the bone marrow after HLI. This is in line with earlier reports that monocytes
are mobilized from the bone marrow after HLI44. In that report, the pro-arteriogenic
potential of monocytes was described to originate from a specific “pro-inflammatory”
subtype, which is characterized by high expression of Ly6C. These Ly6Chi monocytes are
recruited in the early stage of collateral remodeling44, 45 and our data confirm that they are
mobilized from the bone marrow in WT mice. In contrast, recruitment of monocytes proved
to be severely impaired in PCAF−/− mice. PCAF−/− mice showed reduced numbers of
circulating monocytes following HLI, particularly reduced numbers of Ly6Chi monocytes.
Whereas monocytes migrated away from the bone marrow in WT mice, PCAF−/− mice
showed an increase in bone marrow monocytes, suggesting a defect in monocyte
mobilization. Concomitantly, 24 hours after HLI fewer monocytes were recruited to the
collaterals in PCAF−/− mice. Monocytes stimulate arteriogenesis by secretion of growth
factors and degradation of extracellular matrix at the site of collateral remodeling.
Therefore, the lack of monocyte accumulation along collaterals likely contributes to the
impaired arteriogenesis in PCAF−/− mice.
Besides monocytes, PCAF also affected numerous other leukocyte subtypes. In
PCAF−/−mice, we demonstrated decreased numbers of circulating leukocytes involved in
arteriogenesis, like T cells46 (predominantly activated CD4+ T cells7, 11), natural killer
cells11 and regulatory T cells9, 10, and also in those cells that have not previously been
implicated in arteriogenesis, including B cells. Furthermore, fewer dendritic cells were
found in draining inguinal lymph nodes compared to WT mice, where the interaction
between antigen-presenting dendritic cells and T cells takes place. Interestingly, nearly all
subtypes were increased in the bone marrow of PCAF−/− mice, after HLI. This indicates that
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PCAF deficiency interferes with recruitment of pro-arteriogenic leukocytes from the bone
marrow reservoir47.
In conclusion, PCAF−/− mice demonstrated impaired collateral remodeling after HLI,
together with a reduction in the number of native pre-existing collaterals present before
arterial obstruction. PCAF deficiency resulted in altered expression of a large number of
genes, including those in immune and inflammatory pathways, and an attenuated
inflammatory response in multiple cell types involved in arteriogenesis. These findings
indicate that PCAF is a key regulator in post-ischemic blood flow recovery by impacting the
inflammatory processes required for robust arteriogenesis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Although the induction of arteriogenesis is a promising therapeutic alternative to surgical
interventions for patients with severe peripheral arterial disease, clinical trials aimed at
modulating individual growth factors or cytokines have thus far not been as successful as
anticipated. Master switches for multiple relevant gene programs will likely be a more
effective strategy to stimulate arteriogenesis. The transcriptional co-activator P300/CBP-
associated factor (PCAF) acts as such a master switch, as it induces multiple
inflammatory processes crucial to arteriogenesis. Here, we show that PCAF is an
essential factor in arteriogenesis in a model for peripheral arterial disease. Our findings
clearly demonstrate that PCAF plays a key role in the formation of native pre-existing
collateral arterioles and post-ischemic arteriogenesis. PCAF alters the expression of over
3500 genes and impacts inflammatory processes required for effective arteriogenesis,
signifying PCAF as an unanticipated target gene that yields new mechanistic insight in
arteriogenesis.
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Arteriogenesis in PCAF−/− mice. (A) Representative LDPI images (laser Doppler perfusion
imaging) of paws from PCAF−/− and WT mice directly and 7 days after induction of HLI in
the left limb, by double electrocoagulation of the femoral artery. High blood flow is
displayed in red. (B) Quantification of LDPI measurements of PCAF−/− and WT mice over
time. Data are calculated as the ratio of ligated over non-ligated paw. (C) Quantification of
LDPI measurements of PCAF−/− and WT mice directly after induction of HLI. Data are
calculated as the ratio of ligated over non-ligated paw. (D) Quantification of necrotic toe
nails of the ligated limb in PCAF−/− and WT mice counted 28 days after HLI. (E).
Immunohistochemical staining of paraffin-embedded adductor muscle group of PCAF−/−
and WT mice 28 days after HLI using anti-αSMA (red) antibodies. Lumen diameter of
αSMA+ vessels is indicated by black bars. Scale bars = 50 μm. (F-H) Number, mean lumen
area (μm2) and total lumen area per section (μm2 / section) of αSMA+ vessels, measured at
the center of the adductor muscle group in ligated and non-ligated limbs of PCAF−/− and
WT mice. Data are calculated as the ratio of ligated over non-ligated paw. All values are
presented as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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Arteriogenesis after pharmacological inhibition of PCAF and assessment of the pre-existing
collateral bed in PCAF−/− mice. (A) Representative LDPI images of paws directly and 7
days after induction of HLI in the left limb, by single electrocoagulation of the femoral
artery. In WT mice, pluronic gel with or without 25 mg/ml Garcinol was applied topically to
the adductor muscle before skin closure. High blood flow is displayed in red. (B)
Quantification of LDPI measurements of WT mice treated with Garcinol or control over
time. (C) Representative images of the pial circulation in PCAF−/− and WT mice. White
asterisks indicate collateral arteries between anterior, middle and posterior cerebral arteries
(ACA, MCA and PCA, respectively). Following exsanguination and maximal dilation of the
dorsal cerebral circulation, Microfil™ was used as a casting agent, after which the whole
brain was fixated in 4% PFA. (D) Pial collateral density was calculated in PCAF−/− and WT
mice by dividing the sum of ACA to MCA, ACA to PCA and MCA to PCA by the surface
area of the cerebral hemispheres. (E) Region of the brain utilized for calculation of pial
density. Areas were excluded when they were damaged, had poor filling with Microfil™, or
were otherwise uncountable. NS = non-significant. All values are presented as the mean ±
SEM. *P < 0.05, PCAF−/− versus WT.
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The role of PCAF in in vitro inflammatory response. (A) Inflammatory response of whole
blood from PCAF−/− and WT mice was evaluated. Blood from tail vein was collected,
diluted (1:25) and incubated 24 h with LPS (0-500 ng/ml). TNFα (pg/ml) level in cell-free
supernatant was measured by ELISA. ND = non-detectable. (B) Splenocytes of PCAF−/−
and WT mice were cultured and incubated for 24 h with LPS (300 ng/ml) or control.
Splenocytes of WT mice were also incubated with Garcinol (20 μM) in combination with
LPS (300 ng/ml) or control. Cell-free supernatant MCP-1 (pg/ml) level was measured by
ELISA. (C) VSMCs of PCAF−/− and WT mice were cultured and incubated for 24 h with
LPS (0.1 and 1 ng/ml) or control. VSMCs of WT mice were also incubated with Garcinol
(15 μM) in combination with LPS (0.1 and 1 ng/ml) or control. Cell-free supernatant MCP-1
(pg/ml) level was measured by ELISA. (D) Vascular smooth muscle cells (VSMCs) of
PCAF−/− and WT mice were cultured and incubated for 24 h with LPS (1 ng/ml) or control.
MCP-1 mRNA expression was measured by real-time quantitative PCR. Cts were
normalized against Cts of HPRT1. All values are presented as the mean ± SEM of
triplicates. *P < 0.05, **P < 0.01, ***P < 0.001.
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Gene regulation in PCAF−/− mice after HLI. (A) Immunohistochemical staining on fresh
frozen sections of WT adductor muscle 1 day after HLI, using anti-αSMA (red) and anti-
PCAF (green) antibodies. Cell nuclei were stained with DAPI (blue). Scale bars = 50 μm.
(B) Heatmap of differentially regulated genes in whole-genome expression analysis,
comparing PCAF−/− and WT mice. Included are genes that were significantly different
between PCAF−/− and WT mice (q-value < 5). Data are presented as the fold change in
expression between day 1 (t1) and average preoperative baseline levels (t0), generating t1/
t0avg ratios. Red indicates increased and green indicates reduced expression relative to
average baseline levels. The pie graph illustrates a significant decrease of 1963 genes
(green) and increase of 1542 (red) genes in PCAF−/− relative to WT mice. (C-G) Microarray
validation by real-time quantitative PCR of a selection of relevant regulated inflammatory
factors MMP9, TNFα, CCL9, IRF7, CXCL12 and its receptor CXCR4 (H). The height of
the bars represents the ratio of expression in PCAF−/−(black bars) and WT (white bars) mice
at day 1 over day 0. Cts were normalized against Cts of HPRT1. All values are presented as
the mean ± SEM. *P < 0.05, **P < 0.01, PCAF−/− versus WT.
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Monocyte recruitment in PCAF−/− mice after HLI. (A-C) Flow cytometry analysis of
monocytes before (t0) and 1 day after (t1) HLI in PCAF−/− and WT mice. Values are
presented as total monocyte counts in blood (nx106/mL), spleen (% of total cells) and bone
marrow (% of total cells). (D-F) Flow cytometry analysis of “pro-inflammatory” Ly6Chi
monocytes after HLI in PCAF−/− and WT mice. Values are presented as total Ly6Chi
monocyte counts in blood (nx106/mL), spleen (% of total cells) and bone marrow (% of total
cells). (G-H) Activation state of monocytes and Ly6Chi monocytes measured by mean
fluorescence intensity (MFI) of CD11b. *P < 0.05, **P < 0.01, ***P < 0.001.
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Monocyte recruitment to collateral arteries in PCAF−/− mice after HLI. (A)
Immunohistochemical staining on fresh frozen sections of the adductor muscle group from
PCAF−/− and WT mice 1 day after HLI, using anti-αSMA (red) and anti-MOMA-2 (green)
antibodies. Cell nuclei were labeled with DAPI (blue). Scale bars = 100 μm. (B C)
Quantification of MOMA-2 positive cells in the adductor muscle group of PCAF−/− and WT
before (t0) and 1 day after (t1) HLI. Monocytes were quantified from at least six consecutive
sections per mouse and expressed as the number of MOMA-2 positive cells per section and
as the number of MOMA-2 positive cells in the perivascular space of αSMA+ vessels per
section. *P < 0.05, **P < 0.01.
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